Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Publication|Articles|December 18, 2024
- Pharmaceutical Executive: December 2024
- Volume 44
- Issue 12
Pharmaceutical Executive: December 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive December 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 2 years ago
Trending Forwardalmost 2 years ago
Pharma’s ‘Best-Kept Secret’almost 2 years ago
Seeking More Value, Less Costalmost 2 years ago
Dealmaking Dormant No Morealmost 2 years ago
A Rocky Road for Regulationalmost 2 years ago
DTC's New Era of Engagementalmost 2 years ago
Holding On Tight to AI Wavealmost 2 years ago
The Recipe for Relief: Overcoming Industry Pain Pointsalmost 2 years ago
Pharma Forecasting: Key Markets Investors Can’t Ignorealmost 2 years ago
Introducing Agentic AI: Its Revolutionary Potential in PharmaAdvertisement
Related to this article
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Astellas gains an option on Audax’s IL-12 antibody-cytokine fusion DAX-044, while EVERSANA acquires London-based health economics firm Estima Scientific.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
3
Rebuilding Clinical Data Workflows for the AI Era
4
How Preventative Medications May Impact the Lingering Impact of COVID-19
5